Loading
Nanoplatforms for Cancer Theranostics / Nanoparticles: Synthesis and Applications · Journal article
Discover Nano · August 24, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an in vitro proof-of-concept study demonstrating that fungal-mediated silver nanoparticles (average 78 nm) show antibacterial activity against three Gram-negative and Gram-positive bacteria and cytotoxicity in a lung cancer cell line. The work is exploratory nanotechnology research with no animal models, no clinical data, and no comparison to standard agents, limiting immediate clinical relevance.
In vitro nanoparticle synthesis, characterization, and cytotoxicity study. Cell line: human lung carcinoma A549. Bacteria: clinically relevant pathogens (E. coli, S. aureus, K. pneumoniae). No human subjects or animal models.. Intervention: Penicillium verrucosum RPF011 extract-mediated silver nanoparticles (PV-Ag NPs), average size 78 nm..
Average PV-Ag NP particle size 78 ± 2 nm by HR-TEM, predominantly spherical and polydisperse Characteristic surface plasmon resonance peak at 433 nm by UV–visible spectroscopy confirming nanoparticle formation Potent antibacterial activity demonstrated against E. coli, S. aureus, and K. pneumoniae
No in vivo efficacy or toxicity data; no animal models tested. No specification of replication number, statistical methods, or power calculation for cytotoxicity assay.
This work is preclinical and exploratory; it does not yet establish clinical utility. Practitioners should view this as early-stage nanotechnology research requiring substantial further development, including animal toxicology, pharmacokinetics, and eventual clinical trials before any therapeutic application.
In vitro synthesis and characterization study with cell-based cytotoxicity assay but no in vivo validation, animal models, or clinical testing; early-phase nanotechnology work demonstrating proof-of-concept.
As stated by the source record.
Quoted from the source exactly as published.
This work is preclinical and exploratory; it does not yet establish clinical utility. Practitioners should view this as early-stage nanotechnology research requiring substantial further development, including animal toxicology, pharmacokinetics, and eventual clinical trials before any therapeutic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This study reports the green synthesis of silver nanoparticles (PV-Ag NPs) using a pigment-producing environmental fungus, Penicillium verrucosum (PV) RPF011, as a biological reducing and stabilizing agent. The formation of nanoparticles was initially evidenced by a distinct color change from light to dark brown, corresponding to the reduction of Ag⁺ ions, and was further confirmed by UV–visible spectroscopy showing a characteristic surface plasmon resonance peak at 433 nm. Fourier transform infrared (FTIR) analysis indicated the involvement of proteinaceous biomolecules in the reduction and capping processes, ensuring nanoparticle stability. X-ray diffraction (XRD) patterns revealed the crystalline nature of the synthesized nanoparticles, while high-resolution transmission electron microscopy (HR-TEM) analysis demonstrated that the PV-Ag NPs were predominantly spherical and polydisperse, with an average particle size of 78 ± 2 nm. The biologically synthesized nanoparticles exhibited potent antibacterial activity against clinically relevant pathogens, including Escherichia coli, Staphylococcus aureus, and Klebsiella pneumoniae. Furthermore, in vitro cytotoxicity assays revealed significant anticancer activity against the human lung carcinoma A549 cell line, with an IC50 value of 53.22 ± 1.5 µg/mL. The enhanced bioactivity of PV-Ag NPs can be attributed to their nanoscale dimensions and the presence of bioactive capping agents derived from the fungal extract. Overall, the findings highlight the potential of P. verrucosum-mediated silver nanoparticles as an eco-friendly and cost-effective nanoplatform with dual therapeutic applications in antimicrobial and anticancer treatments. This study underscores the promise of fungal-mediated nanotechnology in developing novel nano-drug formulations for managing infectious diseases and lung cancer. Graphical abstract
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.